1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
(
- Contribution to journal › Article
- 2021
-
Mark
High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
(
- Contribution to journal › Article
- 2020
-
Mark
Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study
(
- Contribution to journal › Article
- 2018
-
Mark
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : Results from the Phase II PROMIX trial
(
- Contribution to journal › Article
- 2017
-
Mark
Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer
(
- Contribution to journal › Article
- 2015
-
Mark
Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.
(
- Contribution to journal › Article
-
Mark
Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.
(
- Contribution to journal › Article
-
Mark
Global transcriptional changes following statin treatment in breast cancer.
(
- Contribution to journal › Article
- 2014
-
Mark
Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.
(
- Contribution to journal › Article
-
Mark
32p * biomarkers and molecular subtypes in primary breast tumors and metastases: associations with liver metastases and outcome.
(
- Contribution to journal › Article